CCTC Transplant Outcomes Research and Evidence-Based Practice

Question 1

SRTR (Scientific Registry of Transplant Recipients) program-specific reports primarily enable transplant coordinators and programs to do which of the following?

Accepted Answer

Compare their program's risk-adjusted outcomes against national expected outcomes benchmarks

Answer

SRTR program-specific reports provide publicly available, risk-adjusted outcome data (graft survival, patient survival, wait times) for each transplant program compared to national expected outcomes. These reports are a primary tool for transplant coordinators and quality teams to identify performance gaps, benchmark against peers, and drive targeted quality improvement initiatives.

Question 2

A transplant center's 1-year kidney graft survival rate is flagged as significantly below the SRTR expected value. Applying a PDCA (Plan-Do-Check-Act) quality improvement cycle, what should happen FIRST?

Accepted Answer

Analyze outcomes data to identify root causes of graft loss before planning any intervention (Plan phase)

Answer

PDCA begins with the Plan phase: systematic data analysis to identify root causes of the performance gap. Implementing changes without root cause analysis (jumping to 'Do') risks costly and potentially harmful interventions that miss the actual problem. The specific cause (e.g., rejection, surgical complications, infection, non-adherence) determines the appropriate intervention.

Question 3

A study comparing tacrolimus to cyclosporine for prevention of acute rejection reports a p-value of 0.03. What is the correct interpretation of this p-value?

Accepted Answer

There is a 3% probability of observing results this extreme (or more extreme) if there were truly no difference between the drugs

Answer

A p-value of 0.03 means: if the null hypothesis (no difference between drugs) were true, there would be only a 3% chance of observing results this extreme by chance alone. A p-value does not measure effect size, clinical importance, or the probability that the null hypothesis is true. Statistical significance (p<0.05) does not automatically equal clinical significance.

Question 4

When reading a clinical trial on a novel induction immunosuppression agent with a primary endpoint of 'biopsy-proven acute rejection at 12 months,' which is the most important limitation for a transplant coordinator to recognize?

Accepted Answer

The 12-month timeframe may not capture late rejection, chronic allograft nephropathy, or long-term graft survival outcomes

Answer

While 12-month biopsy-proven acute rejection is a validated and commonly used surrogate endpoint, it may not predict long-term outcomes like 5- or 10-year graft survival. Chronic rejection, calcineurin inhibitor nephrotoxicity, malignancy, and metabolic side effects emerge over longer time horizons. Coordinators must critically assess whether short-term surrogate endpoints align with patient-centered long-term outcomes.

Question 5

When a transplant program's outcomes are flagged by the SRTR as significantly below expected thresholds for two consecutive reporting periods, which oversight body reviews the program under the UNOS/OPTN membership framework?

Accepted Answer

The UNOS/OPTN Membership and Professional Standards Committee (MPSC)

Answer

Under OPTN bylaws, programs with outcomes below expected thresholds are reviewed by the Membership and Professional Standards Committee (MPSC), which can require corrective action plans, enhanced monitoring, or in extreme cases recommend membership actions. This is separate from — and in addition to — CMS oversight and Joint Commission accreditation review.

CCTC - Certified Clinical Transplant Coordinator Practice Test

CCTC - Certified Clinical Transplant Coordinator Practice Test

CCTC Transplant Outcomes Research and Evidence-Based Practice